Cargando…

Staying well after depression: trial design and protocol

BACKGROUND: Depression is often a chronic relapsing condition, with relapse rates of 50-80% in those who have been depressed before. This is particularly problematic for those who become suicidal when depressed since habitual recurrence of suicidal thoughts increases likelihood of further acute suic...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, J Mark G, Russell, Ian T, Crane, Catherine, Russell, Daphne, Whitaker, Chris J, Duggan, Danielle S, Barnhofer, Thorsten, Fennell, Melanie JV, Crane, Rebecca, Silverton, Sarah
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859374/
https://www.ncbi.nlm.nih.gov/pubmed/20302615
http://dx.doi.org/10.1186/1471-244X-10-23
_version_ 1782180503444520960
author Williams, J Mark G
Russell, Ian T
Crane, Catherine
Russell, Daphne
Whitaker, Chris J
Duggan, Danielle S
Barnhofer, Thorsten
Fennell, Melanie JV
Crane, Rebecca
Silverton, Sarah
author_facet Williams, J Mark G
Russell, Ian T
Crane, Catherine
Russell, Daphne
Whitaker, Chris J
Duggan, Danielle S
Barnhofer, Thorsten
Fennell, Melanie JV
Crane, Rebecca
Silverton, Sarah
author_sort Williams, J Mark G
collection PubMed
description BACKGROUND: Depression is often a chronic relapsing condition, with relapse rates of 50-80% in those who have been depressed before. This is particularly problematic for those who become suicidal when depressed since habitual recurrence of suicidal thoughts increases likelihood of further acute suicidal episodes. Therefore the question how to prevent relapse is of particular urgency in this group. METHODS/DESIGN: This trial compares Mindfulness-Based Cognitive Therapy (MBCT), a novel form of treatment combining mindfulness meditation and cognitive therapy for depression, with both Cognitive Psycho-Education (CPE), an equally plausible cognitive treatment but without meditation, and treatment as usual (TAU). It will test whether MBCT reduces the risk of relapse in recurrently depressed patients and the incidence of suicidal symptoms in those with a history of suicidality who do relapse. It recruits participants, screens them by telephone for main inclusion and exclusion criteria and, if they are eligible, invites them to a pre-treatment session to assess eligibility in more detail. This trial allocates eligible participants at random between MBCT and TAU, CPE and TAU, and TAU alone in a ratio of 2:2:1, stratified by presence of suicidal ideation or behaviour and current anti-depressant use. We aim to recruit sufficient participants to allow for retention of 300 following attrition. We deliver both active treatments in groups meeting for two hours every week for eight weeks. We shall estimate effects on rates of relapse and suicidal symptoms over 12 months following treatment and assess clinical status immediately after treatment, and three, six, nine and twelve months thereafter. DISCUSSION: This will be the first trial of MBCT to investigate whether MCBT is effective in preventing relapse to depression when compared with a control psychological treatment of equal plausibility; and to explore the use of MBCT for the most severe recurrent depression - that in people who become suicidal when depressed. TRIAL REGISTRATION: Current Controlled Trials: ISRCTN97185214.
format Text
id pubmed-2859374
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28593742010-04-27 Staying well after depression: trial design and protocol Williams, J Mark G Russell, Ian T Crane, Catherine Russell, Daphne Whitaker, Chris J Duggan, Danielle S Barnhofer, Thorsten Fennell, Melanie JV Crane, Rebecca Silverton, Sarah BMC Psychiatry Study protocol BACKGROUND: Depression is often a chronic relapsing condition, with relapse rates of 50-80% in those who have been depressed before. This is particularly problematic for those who become suicidal when depressed since habitual recurrence of suicidal thoughts increases likelihood of further acute suicidal episodes. Therefore the question how to prevent relapse is of particular urgency in this group. METHODS/DESIGN: This trial compares Mindfulness-Based Cognitive Therapy (MBCT), a novel form of treatment combining mindfulness meditation and cognitive therapy for depression, with both Cognitive Psycho-Education (CPE), an equally plausible cognitive treatment but without meditation, and treatment as usual (TAU). It will test whether MBCT reduces the risk of relapse in recurrently depressed patients and the incidence of suicidal symptoms in those with a history of suicidality who do relapse. It recruits participants, screens them by telephone for main inclusion and exclusion criteria and, if they are eligible, invites them to a pre-treatment session to assess eligibility in more detail. This trial allocates eligible participants at random between MBCT and TAU, CPE and TAU, and TAU alone in a ratio of 2:2:1, stratified by presence of suicidal ideation or behaviour and current anti-depressant use. We aim to recruit sufficient participants to allow for retention of 300 following attrition. We deliver both active treatments in groups meeting for two hours every week for eight weeks. We shall estimate effects on rates of relapse and suicidal symptoms over 12 months following treatment and assess clinical status immediately after treatment, and three, six, nine and twelve months thereafter. DISCUSSION: This will be the first trial of MBCT to investigate whether MCBT is effective in preventing relapse to depression when compared with a control psychological treatment of equal plausibility; and to explore the use of MBCT for the most severe recurrent depression - that in people who become suicidal when depressed. TRIAL REGISTRATION: Current Controlled Trials: ISRCTN97185214. BioMed Central 2010-03-19 /pmc/articles/PMC2859374/ /pubmed/20302615 http://dx.doi.org/10.1186/1471-244X-10-23 Text en Copyright ©2010 Williams et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study protocol
Williams, J Mark G
Russell, Ian T
Crane, Catherine
Russell, Daphne
Whitaker, Chris J
Duggan, Danielle S
Barnhofer, Thorsten
Fennell, Melanie JV
Crane, Rebecca
Silverton, Sarah
Staying well after depression: trial design and protocol
title Staying well after depression: trial design and protocol
title_full Staying well after depression: trial design and protocol
title_fullStr Staying well after depression: trial design and protocol
title_full_unstemmed Staying well after depression: trial design and protocol
title_short Staying well after depression: trial design and protocol
title_sort staying well after depression: trial design and protocol
topic Study protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859374/
https://www.ncbi.nlm.nih.gov/pubmed/20302615
http://dx.doi.org/10.1186/1471-244X-10-23
work_keys_str_mv AT williamsjmarkg stayingwellafterdepressiontrialdesignandprotocol
AT russelliant stayingwellafterdepressiontrialdesignandprotocol
AT cranecatherine stayingwellafterdepressiontrialdesignandprotocol
AT russelldaphne stayingwellafterdepressiontrialdesignandprotocol
AT whitakerchrisj stayingwellafterdepressiontrialdesignandprotocol
AT duggandanielles stayingwellafterdepressiontrialdesignandprotocol
AT barnhoferthorsten stayingwellafterdepressiontrialdesignandprotocol
AT fennellmelaniejv stayingwellafterdepressiontrialdesignandprotocol
AT cranerebecca stayingwellafterdepressiontrialdesignandprotocol
AT silvertonsarah stayingwellafterdepressiontrialdesignandprotocol